CD22 and acute lymphoblastic leukemia: Resistance to Moxe in ALL was also linked to alternative splicing of CD22 mRNA and to genome methylation (91, 92), while CD22 antigen downregulation in leukemic cells by monocyte trogocytosis via FcγR was described in the context of other anti-CD22 targeted therapies (93).